DSM Pharmaceutical Products had lined up a client for its new biologics plant in Australia even ahead of it opening. But as it officially goes online, it has added yet another deal to the roster.
The contract manufacturing arm of the Dutch-based Royal DSM officially opened the $65 million facility Wednesday. The first custom mammalian-based biopharmaceutical manufacturing facility in Australia, it is a pet project of Australia's $345 million Translational Research Institute, which is being built to attract medical research to Australia. The Dutch company has gotten support from the governments of Queensland and the Commonwealth to build the plant.
The plant uses single-use technology and has an output capacity of 500 kilograms. It was built so it could expand that capacity as needed. The company is starting process development work and technical production runs now and expects to start commercial production in January.
The company said Tuesday that it had a new deal to develop and manufacture an eye drug candidate for Melbourne, Australia-based Opthea. Process development will be done at DSM's facility in The Netherlands, but the manufacturing will happen in Brisbane. Last year, it said it had lined up a deal for process development and manufacture of the lead recombinant human protein from Paranta Biosciences, also of Melbourne.
- here's the release
- more from the company
Related Articles:
DSM sets June launch for Australian biologics plant
DSM snags project to feed Australian biologics plant
DSM expands CMO biz with first Brazilian deal